This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Sarcoma	Microsomal glutathione S-transferase 1 (MGST1)	<i>In vitro</i> studies suggest that MGST1 expression could help predict response to chemotherapy and guide choice of therapy for Ewing sarcoma. In 30 primary tumor samples, a genetic screen showed that <i>MGST1</i> expression was associated with doxorubicin sensitivity. Similar results were seen in Ewing sarcoma cell lines. An inhibitor of glutathione S-transferase enzymes was effective against six Ewing sarcoma cell lines. Next steps could include further mechanistic studies to determine the function of MGST1 in drug resistance. Telik Inc's TLK286, a glutathione analog activated by glutathione S-transferase P1-1 (GSTP1; GST P1-1), is in Phase III testing to treat ovarian cancer and non-small cell lung cancer (NSCLC) and Phase II testing to treat breast and colorectal cancer. SciBX 2(15); doi:10.1038/scibx.2009.620 Published online April 16, 2009	Patent and licensing status unavailable	Scotlandi, K. <i>et al. J. Clin. Oncol.</i>; published online March 23, 2009; doi:10.1200/JCO.2008.19.2542 Contact: Katia Scotlandi, Orthopaedic Institute Rizzoli, Bologna, Italy e-mail: katia.scotlandi@ior.it